- Oramed Pharmaceuticals (ORMP +2.7%) has screened the first patients in Phase 2 trial evaluating oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).
- The trial will measure efficacy endpoints via MRI-PDFF (Non-invasive, quantitative assessment of liver fat), for 12-weeks dosing.
- Last week, the company initiated Phase 3 trials of its oral insulin for the treatment of type 2 diabetes.
- https://seekingalpha.com/news/3640914-oramed-launches-late-stage-nash-study-oral-insulin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.